UTv Videos

"This study is significant because it really emphasizes the importance of early detection of both BPH and ED, because knowing that information can really preserve men's quality of life," says Olivia Paulsen.

“Nowadays with PET, it's not perfect, but even with a PSA less than 1 ng/mL, we can detect the site of recurrence about 2/3 of the time,” says Bridget Koontz, MD.

"We found an increased association with AKI or acute kidney injury in the group receiving testosterone replacement therapy," said Evan Panken, MD.

Bajic summarizes his 2024 Sexual Medicine Society of North America Fall Scientific Meeting talk “Penile Prosthesis Biofilms: Friend or Foe?”

"What we found is that costs have really dramatically decreased year by year for all 3 medications," says Ellen Cahill, MD.

"You've got a double pronged attack to kill cancer cells, which is in line with our concepts of immunologic care and immunologic treatment in a variety of cancers, especially cancers such as bladder cancer," says Gary D. Steinberg, MD.

"I think patient preference is going to be the most important thing here," says Raevti Bole, MD.

"We're also dealing with some cultural biases, and we have to be mindful [of] how do people like to discuss sexual medicine, and how does that impact our patient interactions?" says Denise Asafu-Adjei, MD, MPH.

"Having a digital footprint is one of the most important things we can do as health care providers," says Amy Pearlman, MD.

"I think it's great, actually, that finally, we have more data on nutrition that we can recommend to our patients," says Stacy Loeb, MD, MSc, PhD (hon).

"Looking at the survey results, we found that about 40% of men under the age of 40 are interested, at least, in supplementing their testosterone," says Justin Dubin, MD.

"We see [urinary incontinence] in up to 62% of US women, and we know that in women with incontinence, about 25% report that it negatively impacts their sexual health," says Ramzy T. Burns, MD.

"The TRAVERSE trial is the largest randomized placebo-controlled trial ever published in men receiving testosterone vs placebo," says Mohit Khera, MD, MBA, MPH.

"As with any drug, I think there's a big learning curve that comes anytime something's approved," says Landon Trost, MD.

“Particularly [in] bladder cancer, there's 2 new drugs on the market that are exceptionally expensive, but they do provide benefit to patients,” says Geoffrey N. Sklar, MD, FACS.

“So, this study is really getting at that question, could radiation target the lesions that we see on PET, and could we delay hormone therapy for men?” says Bridget Koontz, MD.

"This is a very exciting time for nuclear medicine and molecular medicine," says Jitesh Dhingra, MD, FRCEM.

"Aquablation is like no other transurethral therapy that has come about in the last 100 years," says Ravi Munver, MD.

“So, we have all of this new technology that's about a year old, making surgery a lot safer for patients, making things more efficient, and [giving us] the ability to see stone removal happening from a perspective where we can visualize stone clearance in a way that we haven't been able to before,” says Marcelino E. Rivera, MD.

“We need to close that gap, and just as a general rule, screen our prostate cancer patients more closely for depression, especially those with androgen deprivation therapy,” says Mihir S. Shah, MD.

"[Aquablation] is the only therapy that offers the benefits of a true resective therapy, which is what it is, as well as a non-resective therapy," says Ravi Munver, MD.

“We noticed that if you were White and had prostate cancer and received androgen deprivation therapy, you were more likely to be diagnosed with depression compared to your Black counterparts,” says Mihir S. Shah, MD.

"Both AR and neuroendocrine marker expressions in mCSPC patients at baseline is associated with worse prognosis," says Cedric Pobel, MD.

"When we looked at the same phenotypic data, but focusing on each immunochemistry protein markers, we had 10 patients with AR negative tumor with clearly worse prognosis, and synaptophysin-positive and chromogranin A-positive patients also had a worse prognosis," says Cedric Pobel, MD.

"At the University of Michigan, we've actually started to offer prostate MRI without contrast for patients on active surveillance, which has been a really exciting change," says Benjamin Pockros, MD, MBA.

"I would say the take-home message is that we found that from a patient-centered orientation, telehealth for new and established patients have comparably high satisfaction scores but provide substantially lower costs compared with in-person visits for patients with urologic cancer," says Daniel Carson, MD, MS.

"Patient-reported satisfaction scores were high for both telehealth and inpatient visits for both new and established encounters," says Daniel Carson, MD, MS.

"As we expected, the MRIs with contrast were far more expensive," says Benjamin Pockros, MD, MBA.

“If you haven't used HYDROS before, or if you're concerned about doing bigger glands or tackling more difficult cases, I think we've shown in our first 35-40,000 cases that Aquablation, the therapy, is a valid therapy,” says Lewis S. Kriteman, MD, FACS.

"The idea is to keep improving these devices," says Ana Lidia Flores-Mireles, PhD.